2024-11-25 09:35:45
Antengene Announces First Patient Dosed with Claudin 18.2 Antibody-Drug Conjugate ATG-022 for the Treatment of Patients with Advanced or Metastatic Solid Tumors in Australia
Corporate/ 2023-07-24
Antengene Announces First Patient Dosed ...

Discovered and developed in-house by Antengene\'s R&D team, ATG-022 is an antibody-drug-conjugate (ADC) targeting the Tumor Associated A...

Verbal Beginnings partners with The Clinician to launch a Patient Reported Outcomes Program for Children with Autism Spectrum Disorder
Health/ 2023-07-22
Verbal Beginnings partners with The Clin...

COLUMBIA,Md.,March 29,2023--A leading US-based Applied Behavior Analysis (ABA) therapy provider,Verbal Beginnings,has partnered with The Cli...

CUSMail

CusMail provide the Latest News , Business and Technology News Release service. Most of our news is paid for distribution to meet global marketing needs. We can provide you with global market support.

© CUSMAIL. All Rights Reserved. Operate by Paid Release